Optimizing omega-3 supplementation to resolve inflammation in a personalized medicine CVD prevention

Purpose and goal

This project aims to introduce personalized medicine for an optimized omega-3 fatty acid treatment in cardiovascular prevention. More specifically, the goal is to develop a personalized medicine CVD prevention decision tool to determine if omega-3 treatment is likely to be beneficial in individual patients, and determine what PUFA, dose, and formulation to use for an optimized response towards cardiovascular health.

Expected effects and result

The anticipated outcome of the project is the digital decision support system (DSS) OmegaPerMed Prevention Tool that can identify responders and non-responders to omega-3 treatment. This could hence be the first personalized medicine tool to be widely implemented in international CVD treatment guidelines for secondary prevention to the benefit of large patient population in Europe and world-wide. In addition, it has the potential to be expanded towards personalized dietary PUFA recommendations for primary CVD prevention and other non-CVD associated with chronic inflammation.

Planned approach and implementation

This multidisciplinary project will explore well characterized cohorts and clinical trials for interactions between genes, polyunsaturated fatty acid (PUFA) exposure, cardiovascular disease risk and lipidomic markers towards beneficial effects of omega-3 PUFA. Complimentary lipidomic methods will be employed for mapping PUFA, PUFA sources, and PUFA-derived mediators as biomarkers. All available data will be integrated using artificial intelligence to develop the OmegaPerMed Prevention Tool, which will be continuously tested in a feasibility trial.